

Chong Chyn Chua

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3430742/publications.pdf>

Version: 2024-02-01

24
papers

728
citations

933447

10
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

1002
citing authors

#	ARTICLE	IF	CITATIONS
1	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. <i>Pathology</i> , 2022, , .	0.6	2
2	Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3879-3883.	5.2	25
3	Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. <i>Leukemia and Lymphoma</i> , 2022, 63, 2731-2734.	1.3	0
4	The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. <i>Bone Marrow Transplantation</i> , 2021, 56, 2152-2159.	2.4	5
5	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 368-368.	1.4	1
6	Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. <i>Leukemia and Lymphoma</i> , 2020, 61, 848-854.	1.3	3
7	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3517.	1.6	112
8	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. <i>Blood</i> , 2020, 135, 791-803.	1.4	412
9	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	1.4	13
10	Passenger lymphocyte syndrome due to anti-CD3 and anti-CD28 following combined intestinal and renal transplantation. <i>ISBT Science Series</i> , 2019, 14, 183-186.	1.1	2
11	Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 3-12.	1.7	12
12	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. <i>Blood</i> , 2019, 134, 462-462.	1.4	5
13	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	1.4	64
14	Mutational analysis aids the diagnosis of primary myelofibrosis with atypical morphology. <i>Annals of Hematology</i> , 2018, 97, 1101-1102.	1.8	0
15	Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1116-1123.	2.4	13
16	A physician targeted intervention improves prescribing in chronic heart failure in general medical units. <i>BMC Health Services Research</i> , 2018, 18, 206.	2.2	6
17	Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis. <i>Pathology</i> , 2018, 50, 671-674.	0.6	1
18	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). <i>Blood</i> , 2018, 132, 333-333.	1.4	14

#	ARTICLE	IF	CITATIONS
19	Retrospective evaluation of venous thromboembolism: Are all transient provoking events the same?. European Journal of Haematology, 2017, 99, 18-26.	2.2	12
20	Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data?. Internal Medicine Journal, 2017, 47, 1034-1042.	0.8	8
21	Early Bortezomib Failure Predicts Shorter PFS: A Retrospective Analysis from 4 Tertiary Centres in Victoria, Australia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e120-e121.	0.4	0
22	The superficial femoral vein â€“ time to change this misnomer. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 500-502.	1.8	3
23	Retrospective review on isolated distal deep vein thrombosis (IDDVT) â€” A benign entity or not?. Thrombosis Research, 2016, 142, 11-16.	1.7	13
24	Fanconi anemia in 55-year-old identical twins first presenting as fatal post-chemotherapy pancytopenia. American Journal of Hematology, 2016, 91, 1273-1276.	4.1	2